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Recombinant expression of AhRABSTRACT
Recombinant expression of the Aryl Hydrocarbon Receptor (AhR) yields small amounts of lig-
and-binding competent AhR. Therefore, Spodoptera frugiperda (Sf9) cells and baculovirus 
have been evaluated for high level and functional expression of AhR. Rat and human AhR were 
expressed as soluble protein in significant amounts. Expression of ligand-binding competent 
AhR was sensitive to the protein concentration of Sf9 extract, and co-expression of the chaper-
one p23 failed to affect the yield of functional ligand-binding AhR. The expression system 
yielded high levels of functional protein, with the ligand-binding capacity (Bmax) typically 20-
fold higher than that obtained with rat liver cytosol. Quantitative estimates of the ligand-binding 
affinity of human and rat AhR were obtained; the Kd for recombinant rat AhR was indistin-
guishable from that of native rat AhR, thereby validating the expression system as a faithful 
model for native AhR. The human AhR bound TCDD with significantly lower affinity than the 
rat AhR. These findings demonstrate high-level expression of ligand-binding competent AhR, 
and sufficient AhR for quantitative analysis of ligand-binding.
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Abbreviations
TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; AhR, Aryl Hydrocarbon Receptor; GST, glutath-
ione S-transferase; GGAG, GST-green fluorescent protein-AhR- green fluorescent protein; 
LBD, ligand-binding domain; TEF, TCDD toxic equivalency factors; GUS, -glucuronidase; 
MDEG, 25mM MOPS, 1mM DTT, 1mM EDTA, 10% glycerol, pH 7.5; Sf9, Spodoptera fru-
giperda 9 cells; ECL, enhanced chemiluminescence; PAGE, polyacrylamide gel electrophore-
sis; MOI, muliplicity of infection; PCDD, 1,2,3,7,8-pentachlorodibenzo-p-dioxin; TCDF, 
2,3,7,8-tetrachlorodibenzofuran; PCDF, 2,3,4,7,8-pentachlorodibenzofuran; PCB126, poly-
chlorinated biphenyl 126; TCAOB, tetrachloroazoxybenzene.21/2/09 PAGE 2
Recombinant expression of AhRINTRODUCTION
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is a ubiquitous toxin, and a prototypical represent-
ative of a series of chemicals which effect toxicity through a common mechanism, binding to 
the Aryl Hydrocarbon Receptor (AhR) [1, 2]. Mouse genetic studies demonstrated that dioxin 
toxicity is mediated through the AhR locus [2], and the subsequent cloning of the AhR [3, 4] 
characterised the AhR as a transcription factor. The creation of AhR knockout mice enabled a 
confirmation that AhR was required for dioxin toxicity [5] [6] [7] [8].
For a variety of persistent ligands, the affinity of the AhR for the ligand is directly related to 
toxicity endpoints [1, 2].  Hence determining the affinity of ligands for AhR gives key informa-
tion for evaluating toxicity. The AhR ligand-binding assay is exquisitely sensitive to minor 
changes in methodology e.g. [9, 10], and this leads to  large differences (greater than 100-fold) 
in measured affinity of AhR for TCDD between different laboratories, e.g. [1, 10-12]. There-
fore, measured affinity constants for AhR ligands are not necesarily directly comparable be-
tween laboratories. 
There are marked species differences in the toxicity of TCDD [2], and it is important to deter-
mine if these differences are due to binding to the AhR, and if they are common to other ligands 
of the AhR. The relative affinity of the human and mouse AhR for TCDD is known [13-15], but 
the affinity of the human AhR for other ligands has not been determined [12, 16];  this knowl-
edge deficit arises partly because of difficulties in obtaining fresh human tissue, but also be-
cause analysis of AhR in human tissues is affected by the lability and low levels of the human 
AhR [16, 17]. Consequently, it is problematic to compare the affinity of human AhR for ligands 
with AhR affinity data for toxicologically relevant model species, if this latter data is generated 
in a different laboratory.
Hence a recombinant expression system would enable reliable comparison between AhR prep-
arations in the same laboratory under controlled conditions. Whilst reticulocyte lysates are ca-
pable of producing AhR with ligand-binding functionality [3], the amount of AhR produced in 
this system is small and quantitative assays require considerable amounts of lysate [18], effec-
tively precluding this method for comparison of multiple ligands in multiple species. Mamma-
lian cells are also capable of producing small amounts of functional AhR, but Ramadoss et al. 
[19] found limitations in saturation binding analysis in vitro with this system, and were unable 
to determine a Kd for ligand-binding to AhR in vitro. Baculovirus infection of insect (Spodop-21/2/09 PAGE 3
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has been exploited for a variety of transcription factors. Whilst human AhR has been expressed 
in this system [20], there was no quantitative measurement of the amount or affinity of the lig-
and-binding AhR in this system. This is a prerequisite for studies on ligand-binding, and for val-
idating that the AhR is correctly folded. Thus there is a pressing need for a recombinant 
expression system that can yield high levels of functional AhR, and that can be used in a satu-
ration binding analysis to give quantitative measures of ligand affinity with AhRs from different 
species.
We have investigated the use of baculovirus for recombinant expression of the AhR. We char-
acterise the biochemical parameters required for functional expression of the AhR in this sys-
tem, quantify the amount and ligand-binding functionality of expressed AhR, and show that it 
faithfully reflects the native receptor. The high-level expression of functional AhR has numer-
ous applications, and as an example, we use the recombinant rat and human AhR to demonstrate 
and quantify binding affinity for a number of ligands.21/2/09 PAGE 4
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Materials 
TCDD and congeners (PCDD, 1,2,3,7,8-pentachlorodibenzo-p-dioxin; TCDF, 2,3,7,8-tetra-
chlorodibenzofuran; PCDF, 2,3,4,7,8-pentachlorodibenzofuran; PCB126, polychlorinated bi-
phenyl 126) were obtained from Cambridge Isotope laboratories, Mass, USA, at high purity 
(99%). 2,3,7,8-tetrachloroazoxybenzene (TCAOB) was a kind gift from Dr. A. G. Smith (MRC 
Toxicology Unit, Leicester, UK). [3H]-TCDD was obtained from Eagle-Picher (Kansas, USA), 
and was at 27.7 Ci mmol-1. All other chemicals were also of the highest quality available. Rats 
were obtained from Charles River Laboratories, UK.
Sub-cloning of rat and human AhR cDNAs
A rat (Charles River Wistar- CRL:WI) was killed, and liver was homogenised in TRIzol Rea-
gent (Invitrogen). Total RNA was extracted from liver according to the manufacturer’s manual. 
mRNA was purified by Oligotex mRNA Spin-column (Qiagen) according to the manufacturer's 
manual. RT-PCR (Prostar Ultra HF RT-PCR kit (Stratagene)) was used to clone rat AhR and its 
ligand-binding domain sequences according to the manufacturer's instructions. The PCR prim-
ers were designed based on the known Sprague-Dawley rat AhR cDNA sequence (Table 1), and 
the first nine amino acids (leader sequence) were deleted. Rat AhR cDNA was divided into two 
pieces (primers rA5 and rALB3; rABam3 and rLBDreverse), amplified separately and ligated 
together at the BamHI site. Rat AhR ligand-binding domain was amplified by primers rALB5 
(forward), which contains a novel Sal I site, and rALB3 (reverse) containing the Hind III site 
and six-histidine tag. All PCR products were subcloned into either pGEMT-Easy (Promega) or 
pPCR Script (Stratagene) plasmid, and analysed by double-strand DNA sequencing. The AhR 
cDNA clones were then inserted into plasmid pFastBac1 between the SalI and HindIII sites.
Human AHR cDNA, and its ligand-binding domain, were amplified by PCR from plasmid 
pSporthAhr2 (Susan Moran, Mcardle Lab. for Cancer Research, University of Wisconsin-Mad-
sion Medical School); the primers are listed in Table 1. The human AHR-His and hAHR-LBD-
His fragments were then subcloned into Sal I and Hind III sites of plasmid pFastBac1.
The plasmid pFastBac1.Gus (Invitrogen) was used as a positive control to prepare recombinant 
-glucuronidase (GUS) baculovirus, using the same method as described above. Baculovirus 21/2/09 PAGE 5
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(Mayo Graduate School, Rochester, MN 55905, USA).
Site-directed mutagenesis 
Quick-change mutagenesis kit (Stratagene) was used to generate the V381A mutant of the 
hAhR LBD construct, according to the manufacturer’s instructions. The amino acid at 381 is 
variant between rat and human (V/A), and mutation of this amino acid is known to confer high 
affinity binding [13, 14]. The mutant primer is shown in Table 1. The plasmid pFastBac1/
hAhR-LBD was used as the template. The mutation was confirmed by double-stranded DNA 
sequencing.
Expression of recombinant AhRs
The Bac-to-Bac (Invitrogen) system was used to express recombinant AhRs in insect cells. 
Briefly, the plasmids pFastBac1/hAhR-His, pFastBac1/hAhR-LBD-His, pFastBac1/V381A-
His, pFastBac1/rAhR-His and pFastBac1/rAhR-LBD-His were transformed into bacterial strain 
DH10Bac. Bacmids were prepared by Qiagen miniprep, and inserts were confirmed by PCR 
analysis. The bacmids then transfected into Sf9 cells, baculovirus was harvested after 5-7 days 
incubation and then further amplified in infected Sf9 cells to obtain high titre virus. Virus was 
directly titred in a plate assay, and high titre virus stocks were used to infect Sf9 cells and ex-
press recombinant AhRs. Virus was added to Sf9 cell culture, and infected Sf9 cells were har-
vested by centrifugation at 500g for 10 minutes at 48 hours after infection, or as indicated, and 
all subsequent steps were on ice or at 4C. Cell pellets were re-suspended in MDEG buffer 
(25mM MOPS, 1mM DTT, 1mM EDTA, 10% glycerol, pH7.5) containing 20mM molybdate. 
Cells were broken by sonication, and cell debris was removed by centrifugation at 12,000g for 
10 minutes. The supernatant was further centrifuged at 200,000g for 30 minutes. The final cy-
tosolic supernatants were divided into small aliquots and stored at -80C. For diafiltration, cy-
tosol was diafiltered with a 10k Molecular Weight cut-off membrane with MDEG buffer at 4C. 
For addition of ATP/ Mg2+, these were added in MDEG buffer with 2mM ATP, 5mM MgCl2.
Ligand binding assay
The method for [3H]-TCDD binding to AhR was previously established by [1].  Typically, rat 
liver cytosol was diluted to 5mg/ml in MDEG buffer (25mM MOPS, 1mM DTT, 1mM EDTA, 
10% glycerol, pH7.5) containing 20mM molybdate. Then the sample was incubated with [3H]-
TCDD or [3H]-TCDD plus a 200-fold excess of competitor 2,3,7,8-tetrachloroazoxybenzene 21/2/09 PAGE 6
Recombinant expression of AhR(TCAOB) at 4C overnight. After incubation, 30l of dextran-coated charcoal suspension 
(67mg/ml, prepared in MDEG buffer) was added into a 200l sample of the mixture. The sus-
pension was incubated on ice for 10min, and then was centrifuged at 25,000g for 10min. 150l 
of the supernatant was removed and radioactivity was measured in a scintillation counter. Spe-
cific binding was defined as the difference of radioactivity between without (total binding) and 
with competitor TCAOB (non-specific binding). For recombinant rat AhR protein, either 
0.25mg or 0.5mg/ml cytosol protein was used for binding assay, and supplemented with BSA 
to a final protein concentration of 5mg/ml; 1mg/ml recombinant human AhR with 4mg/ml BSA 
was used for assay unless otherwise stated. For competition assay, a serial dilution of competitor 
was incubated with 0.5nM [3H]-TCDD (except where otherwise stated), and the specific bind-
ing was determined as described above. Specific binding or Ki was determined by using non-
linear regression, using Graphpad 4/5, fitting a saturation binding isotherm, or one-site compet-
itive binding equation, to the experimental data. Ki was derived from the IC50 using the Cheng-
Prusoff equation, as implemented in Graphpad.
Hydroxylapatite assay 
200l sample was treated with charcoal as described above; the supernatant was transferred into 
a fresh tube, then 200l 50% hydroxyapatite (HAP) was added. After incubation on ice for 30 
minutes, the HAP resin was spun down at 25000g for 1 minute at 4C. The pellet was washed 
twice with 1ml MDEG buffer containing 0.1% Tween 20, and then the protein was eluted into 
0.5ml ethanol. The supernatant was assayed for radioactivity by liquid scintillation counting. 
Analysis of saturation-binding data was as described for the charcoal assay above.
Western blotting 
Protein was run on polyacrylamide gel electrophoresis (PAGE) (either SDS-PAGE, or pre-cast 
gels (Invitrogen) using lithium dodecyl sulphate), and transferred to a blotting membrane. Sig-
nal was detected using Enhanced Chemiluminescence (ECL; GE Healthcare) and exposure to a 
film. The antibody against p23 was obtained from Stressgen Bioreagents Corporation (Assay 
Designs, Inc., 5777 Hines Drive, Ann Arbor, Michigan 48108 USA). The LBD of the mouse 
AhRb-1 allele cDNA [14] was amplified with oligos 282 and 416 (amino acids 282-416; Ta-
ble 1), and subcloned into the BamHI site of pRSETc (Invitrogen). The AhR LBD was induced 
in BL21(DE3) bacteria, and the insoluble protein was solubilised in 6M guanidine HCl, 50 mM 
Tris, pH 8.0, and purified by Ni2+-affinity chromatography. The purified protein was used to 21/2/09 PAGE 7
Recombinant expression of AhRimmunise rabbits, and antiserum harvested when the bleeds were capable of detecting <1ng of 
antigen.
Statistical analysis 
Data is presented as mean and standard deviation, except where otherwise noted. Statistical 
analysis used t-test where appropriate. For calculation of confidence intervals from saturation, 
and competition ligand-binding, Graphpad 5 was used for calculation of 95% confidence limits 
subsequent to non-linear curve-fitting.21/2/09 PAGE 8
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Generation of baculovirus constructs and expression of protein 
The AhR cDNA was cloned from the liver of a CRL:WI rat, and the sequence of the constructs 
(Accession number AJ821851) was confirmed by double-stranded sequencing to be identical 
for that of the Sprague-Dawley rat (AAA56897). The human and rat cDNAs were cloned into 
recombinant baculovirus, used to infect Sf9 insect cells, and the presence of AhR determined 
using western blotting (Fig. 1A). Cytosol from uninfected cells showed no noticeable cross-re-
activity with the antibody, and cells infected with a virus expressing -glucuronidase also failed 
to show any cross-reactivity, demonstrating that viral infection did not cause any cross-reacting 
proteins. Virus expressing rat and human AhR both gave rise to strong immunoreactive bands 
in cytosol, with the human AhR migrating at a slightly higher apparent molecular mass than the 
rat AhR, consistent with previous reports [22]. This shows that the AhR protein was specifically 
expressed and detected in Sf9 cells. The time course of expression of cytosolic AhR protein was 
examined (Fig. 1B); AhR protein was maximally induced at 48 hours after infection, and this 
time point was used for further studies. Comparison of the amount of AhR protein in total cell 
lysates versus cytosol (Fig. 1C) showed that both the human and rat AhR were more abundant 
in total cell protein, compared to cytosol. This effect was more obvious for the human AhR, than 
for the rat AhR. The full-length and Ligand-Binding Domain (LBD) constructs were then ex-
pressed at an equal Multiplicity of Infection with virus (MOI), to determine if there was ade-
quate expression of the recombinant proteins in cytosol (Fig. 1D). While the expression of the 
full-length human and rat AhR proteins was adequate, the expression of the LBD constructs was 
less than that seen for the full-length constructs. The rat LBD was present in cytosol at accept-
able levels, but the human AhR LBD and the LBD-Val381Ala mutant were present at too low 
a level for comparison with the rat LBD or full-length constructs (Fig. 1D). Thus the Sf9 expres-
sion system yielded high levels of expression of both rat and human full-length AhR proteins in 
cytosolic extracts.
Ligand-binding assay
Given that the expression system yielded cytosolic full-length human and rat AhR protein, it 
was necessary to test whether the protein was capable of specifically binding a ligand; the pro-
totypical ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) was used, with rat liver cytosol 
as a positive control reagent. Fig. 2A, B shows that uninfected Sf9 cytosol (a negative control) 
showed no specific binding to tritiated TCDD, but that rat liver cytosol bound TCDD. Cytosol 21/2/09 PAGE 9
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TCDD, demonstrating that the recombinant AhR protein is capable of binding ligand. The bind-
ing assay was robust to the use of 2,3,7,8-tetrachlorodibenzofuran (TCDF) or tetrachloroazoxy-
benzene (TCAOB) as a competitor to determine specific binding (unpublished data), and the 
amount of specific binding was not significantly different when using a protocol with charcoal, 
or charcoal followed by an additional hydroxyapatite step (Fig. 2C). The assay showed specific 
binding to TCDD with rat liver cytosol (Fig. 2D), with saturation binding analysis for rat cy-
tosol yielding an apparent Kd for TCDD of 1.0 ± 0.45 nMolar (mean ± Standard deviation, n=6), 
and a maximal binding capacity (Bmax) of 52 fmol/mg, within the range of previous estimates 
[1, 10, 12].
Optimisation of recombinant expression for ligand-binding competent AhR
Protein concentration is a key variable for TCDD binding assays, since TCDD solubility is crit-
ically dependent upon protein concentration (DRB, unpublished data; [9, 10]), and hence the 
binding assays were made up to 5 mg/ml final protein concentration with BSA. Although the 
Sf9 cytosols expressing AhR showed specific binding, the specific binding was dependent upon 
the concentration of Sf9 cytosol (DRB, unpublished data). Fig. 3A shows that addition of unin-
fected Sf9 cytosol inhibited the binding of TCDD to recombinant rat AhR in a dose-dependent 
manner, and that the non-specific protein, BSA, did not inhibit binding of TCDD to the AhR. 
Since the binding assay represents the difference between total TCDD in solution, and the 
TCDD present after addition of a ~200-fold molar excess of unlabelled competitor (i.e. the high 
capacity and “non-specific” binding), it was possible that this result could have been caused by 
the addition of the Sf9 cytosol increasing the amount of high-affinity binding sites, such that the 
unlabelled competitor simply bound to the high-affinity binding sites, but was no longer able to 
displace [3H]-TCDD since the high affinity binding sites are in excess. However, Fig. 3B shows 
that dilution of the rat AhR cytosol results in a decrease in the specific binding, and excludes 
the possibility that the Sf9-mediated decrease in binding is due to an increase in the amount of 
specific binding sites. The addition of ATP and Mg2+ to the BSA solution did not affect the spe-
cific binding of the rat AhR, although these agents are known to be essential for hsp90-mediated 
protein interactions with AhR [23]. Extensive diafiltration of the Sf9 cytosol failed to reduce the 
ability of Sf9 cytosol to inhibit the binding of rat AhR to TCDD, excluding the possibility of a 
low molecular weight AhR ligand being present in the Sf9 cytosol (Fig. 3C). Finally, perform-
ing the ligand-binding assay in the presence of a high concentration of TCDD also had no effect 21/2/09 PAGE 10
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of AhR binding sites. The known dependence of AhR folding on protein interactions (e.g. [23, 
24]) suggested that proteins in the Sf9 cytosol may be causing the AhR to adopt an improperly 
folded conformation; to test this, the Sf9 cytosol was heat treated, whereupon it then failed to 
inhibit the binding of rat AhR to TCDD (Fig. 3D). Reticulocyte lysates are known to be able to 
support the folding of AhR into a ligand-binding capable form (e.g. [25] [14]), and so reticulo-
cyte lysate protein was used to determine if the inhibitory effect of Sf9 protein was specific to 
Sf9 cells, or a general phenomenon of cell lysates. Fig. 3E shows that the specific binding of rat 
AhR to TCDD was unaffected by reticulocyte lysate protein over a range of 0-5 mg/ml, thereby 
showing that the effect of Sf9 cytosol in inhibiting the binding of TCDD to recombinant rat AhR 
is specific to the Sf9 cytosol, as opposed to reticulocyte lysate or BSA solution.
It has previously been shown that p23 is an essential chaperone for correct folding of the gluco-
corticoid receptor [21], and it is known that p23 associates with the AhR. In order to determine 
if p23 could enhance the folding of AhR in Sf9 cells, rat AhR was co-expressed with human p23. 
Fig. 4A shows that baculovirus expression of p23 yields sufficient soluble p23 for visual detec-
tion in a coomassie-stained gel, and immunodetection confirmed that the induced band was in-
deed p23, and neither Sf9 cells, nor AhR-encoding baculovirus caused any cross-reactivity 
(Fig. 4B). AhR was co-expressed with p23 protein, and there was no obvious effect on the 
amount of AhR protein that was present in cytosolic extracts in the presence and absence of co-
expression of p23 (Fig. 4C); this was true when the rat AhR was expressed at low levels (MOI 
of 0.1) and at higher levels of expression (MOI=1). The functionality of the expressed rat AhR 
protein was examined by ligand-binding assay, and there was no significant difference in the 
amount of specific binding of TCDD between cytosols containing rat AhR with and without p23 
protein (Fig. 4D). Thus the expression of p23 had no effect on the yield of cytosolic protein, nor 
the functionality of expressed AhR under these conditions in Sf9 cells.
Determination of affinity of rat and human AhR for TCDD
In view of the consistent cytosolic expression of rat and human AhR, and qualitative determi-
nation of ligand-binding ability, saturation binding analysis was undertaken to quantitate the 
amount and affinity of binding. When cytosol containing recombinant rat AhR was produced at 
an MOI of 0.1, the resulting AhR showed saturable binding to TCDD (Fig. 5A), with a Kd of 
1.34 ± 0.32 nM (n=6 independent determinations). This value was not significantly different 
from the values we obtained for the AhR in rat liver cytosol (1.0 ± 0.45nM, n=6, Fig. 2D), dem-21/2/09 PAGE 11
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AhR. The Bmax was 1.5±0.37 pmol/ mg cytosolic protein, ~20-fold higher than in rat liver cy-
tosol (Fig. 2D). Expression of rat AhR with higher MOI yielded slightly higher amounts of cy-
tosolic AhR protein (Fig. 5B), but no increase in the amount of specific binding to TCDD (Fig. 
5C). In order to confirm that the recombinant expression system could functionally express AhR 
from different organisms, the affinity of TCDD for human AhR under optimised conditions was 
determined, yielding a Kd of 2.77± 0.94 nM (n=6), with a Bmax of 0.46±0.12 pmol/mg cytosolic 
protein (Fig. 5D). Although we did not determine the affinity of native human liver AhR, this 
data is consistent with previous reports in showing that the human AhR has a significantly re-
duced affinity for TCDD compared to rat [13] [12, 15] [16].
Determination of ligand affinity by competitive binding assay
In order to determine if the expressed AhR could be used to determine the affinity of other lig-
ands, the rat AhR was used in a competition binding assay for a number of congeners of TCDD 
(Table 2). The competition assays showed good fit to a one-site competitive binding assay equa-
tion, and were robust to replication (data not shown). The rat AhR yielded a Ki for TCDD which 
was not significantly different from the Kd determined from rat liver, or recombinant rat AhR 
(Fig. 5A), demonstrating that the competitive binding assay with recombinant AhR is robust. 
Comparison of the ability of various congeners to bind to rat AhR showed that TCDF and 
PCDD showed a similar affinity as TCDD, but that PCDF was a ~three-fold less potent ligand 
than PCDD, and PCB126 was ~50-fold less potent than TCDD. For the human AhR, TCDD and 
PCDF were ~two-fold less potent than TCDF and PCDD, and PCB126 was ~40-fold less potent 
as a ligand than TCDD (Table 2). The Ki values for the human AhR consistently showed the 
same rank order of potency as in the rat; however, as with the Kd values, the human AhR showed 
a lower affinity for ligands when compared with the rat. Thus these data demonstrate that the 
recombinant AhR can be used for the determination of ligands in a competitive ligand-binding 
assay.21/2/09 PAGE 12
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Recombinant expression of ligand-binding competent AhR would have significant advantages 
for determining the ligand-binding affinity of AhR from a variety of organisms, but expression 
of AhR is problematic. Bacterial expression of AhR yields insoluble protein [18], and even in 
insect cells, the majority of the AhR protein produced was in an insoluble 10 000 g pellet (MQF, 
TJ, unpublished data, [20]). However, the full-length AhR proteins produced cytosolic AhR in 
insect cells, and these levels were readily detectable (Fig. 1C, D). Thus high levels of cytosolic 
expression of full-length AhR proteins was achieved, and it was necessary to determine whether 
these proteins were able to bind ligand.
Surprisingly, the specific binding of TCDD to infected Sf9 cytosols was dependent upon the 
concentration of Sf9 cytosol in the binding reaction (data not shown, Fig. 3A). The ligand-bind-
ing assay for AhR is a complex assay, which depends upon maintaining TCDD in solution by 
low-affinity binding of TCDD to protein or other macromolecules, and so can be prone to arte-
factually induced interpretation arising from distinct constituents between Sf9 cytosol and other 
reagents tested. We firstly demonstrated that this was not due to an artefact, such as the presence 
of small molecular weight ligands in Sf9 cytosol (Fig. 3C), or the failure of the cold competitor 
to saturate specific binding (Fig. 3B, C). The fact that heat treatment of Sf9 cytosol abolishes 
the inhibition of AhR binding (Fig. 3D) suggests that the inhibition is caused by proteins, con-
sistent with previous findings that protein chaperones are essential for AhR folding (e.g. [23, 
26-28]). We specifically tested whether p23 could enhance AhR folding; p23 is known to en-
hance folding of the baculovirus-expressed glucocorticoid receptor in Sf9 cells, and  is required 
for baculovirus-expressed human AhR and ARNT to bind to DNA response elements [29]. 
However, p23 alone had no effect on AhR solubility or ligand-binding (Fig. 4); this is in con-
trast to the requirement for p23 with glucocorticoid receptor in Sf9 cells [21]. Thus it remains 
unclear exactly what proteins are involved in the proper folding of AhR, and this is a key issue 
for obtaining high yields of AhR for structural studies.
Recombinant cytosolic AhR was tested for ligand-binding functionality, and reproducibly pro-
duced saturable ligand-binding to TCDD (Fig. 5A). The Kd for the recombinant expressed AhR 
was not significantly different from that determined with rat liver cytosols using the same ex-
perimental protocol (Fig. 2, Fig. 5), and these are in turn directly comparable with previous de-
terminations [12] [10] [30]. We did not have access to fresh human liver to undertake an 
analysis of native human AhR ligand affinity, but the affinity of the recombinant human AhR 21/2/09 PAGE 13
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using baculovirus yields protein with similar ligand-binding functionality to the native form, 
and validates the use of recombinant AhR. The relatively high levels of expression of functional 
recombinant AhR described in this report is an important advance, as this is the first system that 
generates sufficient functional receptor for e.g. comprehensive ligand-binding studies or protein 
purification/ structural analyses.
Several invertebrate species have been characterised to have non-ligand-binding AhR genes 
[33-35], and so it is likely that Spodoptera cells also lack a ligand-binding AhR. In agreement 
with this, we were unable to detect any reproducible or significant specific binding of [3H]-
TCDD in Sf9 cells. However, Sf9 cells are capable of folding the rat and human AhR into a lig-
and-binding conformation (Fig. 5) that is functionally indistinguishable from the native receptor 
in terms of Kd. It is apparent that there are no species-specific co-factors that are required for 
functional reconstitution of ligand-binding functionality of the human or rat AhR. Given the low 
endogenous background of binding, and the ability to fold heterologous AhR, it is likely that 
this system will have broad applicability in functional expression of AhR from diverse species.
The human and rat AhR showed robust and saturable ligand-binding affinity for TCDD (Fig. 5),  
consistent with previous data [12-14], and hence can be used for further ligand-binding analysis. 
We undertook a comparison of the ability of rat AhR to bind TCDD, and the value in competi-
tive binding assay was not significantly different from that obtained in an equilibrium binding 
analysis (Table 2). The rat AhR showed specific binding to a range of dioxins and furans, in 
agreement with prior estimates [1, 2]. The human AHR bound specific ligands in the same rank 
order of affinity as the rat, but with lower affinity than the rat AhR (Table 2), consistent with 
the results in Figure 5. The lower affinity of the human AHR for these ligands may lead to ar-
tefactually high values for Ki, as the solubility of e.g. TCDD in protein solution declines dra-
matically at concentrations much in excess of 2 nM (unpublished data). These experiments have 
been performed under the same conditions, which enhances the reliability of the comparison, 
and are novel information in defining the affinity of human AHR for environmentally-important 
ligands. The congeners described account for a substantial proportion (~90%) of the human di-
etary exposure to dioxin-like congeners, or TEQ (MR, AF, SW, unpublished data, [36]). Since 
receptor-ligand binding is required for any subsequent activation of a receptor, and coupling to 
biological effect, it follows that the affinity of the AhR for ligand is a key determinant for the 21/2/09 PAGE 14
Recombinant expression of AhRsubsequent biological actions. Thus the use of the baculovirus expression system for functional 
expression of AhR should have important applications in risk assessment.
In summary, these results show that functional rat and human AhR can be expressed using the 
baculovirus expression vector system, and that robust and saturable ligand-binding is obtained 
which is directly comparable to the native receptor. The high yield of functional AhR is a sig-
nificant advantage for this system, and consequently quantitative analysis of ligand-binding can 
readily be performed. Our results characterise the binding of a variety of ligands and show that 
this expression system can be readily applied for determining the affinity of ligands for AhR 
from two model species.21/2/09 PAGE 15
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Recombinant expression of AhRFIGURES
Fig. 1.  Recombinant expression of AhR protein in Sf9 cells. (A) Sf9 cells were uninfected 
(Sf9), or infected with baculovirus (at an MOI of 10) encoding -glucuronidase (Gus), rat AhR 
(rAhR) or human AhR (hAhR); cells were lysed 48 hours after infection, and cytosol prepared 
as described in the methods section. 10 g of cytosolic protein was western blotted, and detected 
with a polyclonal antibody against the AhR; signal was visualised by ECL. The position of the 
molecular weight markers (M) is shown in kDa. (B) Sf9 cells were uninfected (Sf9), or infected 
with rat AhR virus (rAhR), and cytosol prepared at the indicated time after infection.10 g of 
cytosolic protein was western blotted for AhR as described in (A). (C) Cytosol (C) or total pro-
tein (T) was isolated from Sf9 cells infected (MOI=10) with rat AhR, or human AhR, at 48 hours 
after infection; total protein from uninfected Sf9 cells is a control lane. 10 g of protein was 
western blotted for AhR as described in (A). (D) Sf9 cells were infected at MOI=10 and cytosol 
prepared 48 hours later. Cells were uninfected (Sf9), or infected with virus encoding  -glucuro-
nidase (Gus), rat AhR (rAhR), rat AhR Ligand-Binding Domain (LBD) (rLBD) or human AhR 
(hAhR), human AhR LBD (hLBD), or the V381A mutant of the human AhR LBD (hVA); sam-
ples were western blotted with an antibody against the AhR, and detected by ECL. The position 
of the full-length AhR and the AhR LBD proteins is shown by an arrow; a band of cross-reactive 
protein is indicated by a line. The position of the molecular weight markers (M) is shown in 
kDa.
Fig. 2.  Specific binding of TCDD by recombinant baculovirus extracts. (A) cytosol was 
prepared from rat liver, Sf9 cells (Sf9) or Sf9 cells infected with rat AhR (rrAhR), as described 
in Fig. 1. Cytosol was assayed for ligand-binding as described in materials and methods, with 
rat liver and Sf9 cytosol at 5 mg/ml, and 0.5 mg/ ml rat AhR cytosol made up to 5 mg/ml with 
BSA; [3H]-TCDD is present in the binding assay at a concentration of 1nM. Specific binding is 
shown in disintegrations per minute (DPM). Results are shown as mean ± SD (n=3); results are 
representative of multiple experiments. (B) the binding assay was carried out as for A, except 
that the cytosol from Sf9 cells infected with virus encoding human AhR (rhAhR), had a protein 
concentration of 1 mg/ml, made up to 5 mg/ml with BSA. (C) rat liver cytosol was subjected to 
a binding assay, as described in materials and methods. After charcoal adsorption (Charcoal on-
ly), the total radioactivity in solution (Total) was compared to that with a 200-fold excess of 
TCAOB (Non-specific), and the Specific binding (Specific) is the total minus non-specific 
binding. Alternatively, the post-charcoal supernatant was subjected to hydroxyapatite treatment 21/2/09 PAGE 17
Recombinant expression of AhR(Charcoal + HAP), and the Total, Non-specific and Specific are shown. Results are shown as 
mean ± SD (n=3). (D) rat liver cytosol (5 mg/ml) was subjected to saturation binding analysis, 
and specific binding analysed by non-linear regression, as described in the materials and meth-
ods. For this experiment, the Kd is 0.75 nM (95% Confidence limits 0.54-0.96nM), and the Bmax 
is 52 fmol/mg cytosolic protein.
Fig. 3.  Factors affecting specific binding of rat AhR in Sf9 cytosol. (A) TCDD binding as-
says were performed as described in Figure 2, with the exception that cytosol from uninfected 
Sf9 cells (Sf9 cytosol) was titrated in at the indicated concentration. Results are shown as mean 
± SD (n=3), and are representative of results obtained on at least two occasions. (B) as for A, 
but the concentration of Sf9 cytosol containing rat AhR was varied. (C) as for A, with the ex-
ception that Sf9 cytosol from uninfected cells was diafiltered as indicated, or the TCDD binding 
assay was performed in the presence of 5nM TCDD (instead of 1nM) where indicated. (D) As 
for A, with the exception that the Sf9 cytosol from uninfected cells was subject to heat treatment 
(65C for 10 minutes) prior to use in the assay, as indicated. (E) as for A, but rabbit reticulocyte 
lysate and BSA were used to make the rat AhR up to 5 mg/ ml protein concentration.
Fig. 4.  Coexpression of p23 and rat AhR in Sf9 cells. (A) Sf9 cells were infected with p23 
(at an MOI of 1; p23), and/ or with rat AhR (rAhR), at the indicated MOI. Uninfected Sf9 cells 
(Sf9) were used as a control. Total (T) or cytosolic (C) fractions were isolated, and 10 g of pro-
tein was electrophoresed, followed by staining of the gel with coommassie blue. The position 
of molecular weight markers (M) is indicated. (B) the samples in A were subjected to western 
blotting and immunodetected with an antibody against p23, using methodology as described in 
Fig. 1. (C) cytosol was prepared from cells infected with p23 (MOI=1), and rat AhR (rAhR) at 
the indicated MOI; cells infected with p23 alone served as a control. The samples were western 
blotted with an antibody to AhR, as described in Fig. 1. (D) Samples of cytosol prepared from 
an infection with rat AhR at an MOI of 0.1 (rAhR), with or without p23 at an MOI of 1 
(rAhR+p23), and uninfected Sf9 cells (Sf9) were used for a TCDD binding assay, using standard 
conditions as described in materials and methods. Results are shown as mean ± SD (n=3).
Fig. 5.  Effect of expression level of AhR on AhR functionality. (A) Sf9 cytosol was pre-
pared after infection with rat AhR-encoding baculovirus at an MOI of 0.1, and assayed for sat-
uration binding; a typical experiment is shown, with each data point representing triplicate 
determinations, and showing mean ± SD (n=3). The Kd was 1.35nM, and the Bmax was 1.83 21/2/09 PAGE 18
Recombinant expression of AhRpmol/mg. (B) western blotting of AhR. Sf9 cells were infected with virus encoding rat AhR at 
an MOI of 0.1-10 (as indicated). Cytosol samples were prepared at 48 hours after infection, and 
10 g of each sample western blotted for AhR, as described in Fig. 1. (C) cytosol samples pre-
pared at different MOIs, as described in (B), were assayed for TCDD binding, with the addition 
of uninfected Sf9 cytosol (Sf9), and rat liver cytosol as a positive control. Results are shown as 
mean ± SD (n=3). (D) A representative saturation binding isotherm for recombinant human 
AhR is shown, with  each data point representing triplicate determinations, and showing mean 
± SD (n=3). The Kd was 2.6 nM, and the Bmax was 0.42 pmol/mg. 21/2/09 PAGE 19
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TABLE 1: Sequence of oligonucleotides used in PCR
Gene name
primer Sequence
Rat AhR
AAA56897
rALB5 (forward) gtcgacatgGCAATGAATTTCCAAGGGAGGTTAAAGTATC
rALB3 (reverse) aagcttctagtgatggtgatggtgatgCAAGGGATCCATTATGGGAGAGAAAGG
rA5 (forward) gtcgacatgGGCAGCCGCAAGCGGCGC
rABam3 (forward) CTCTCCCATAATGGATCCCTTGC
rLBDreverse AAGCTTCTAGTGATGGTGATGGTGATGCAGGAATCCGCTGGGTGTGATATCAGG
Human AhR
AAA16210
hA5 (forward) gtcgacatgGCCAGTCGCAAGCGGCGGAAG
hA3 (reverse) aagcttctagtgatggtgatggtgatgCAGGAATCCACTGGATGTCAAATCAGG
hALB5 (forward) gtcgacatgGCAATGAATTTCCAAGGGAAGTTAAAGTATC
hALB3 (reverse) aagcttctagtgatggtgatggtgatgTAAGGGATCCATTATGGCAGGAAAAGG
V381A CCAGATTATATCATTGCAACTCAGAGACCGTTAACAGATGAGGAAGGAAC
PCR Primers for cloning rat and human AhR and its ligand-binding domain.  Sequences based on SD rat 
AhR are shown in capital letters. Introduced restriction sites are shown by underlining, the start codon is 
shown in bold, and the hexa-histidine sequence is also in bold font. For the mutagenesis oligo (V381A), the 
mutated codon is in bold, and the selection restriction enzyme site is underlined. Sequences are shown 5’ to 
3’.
TABLE 2: Competitive binding assay for AhR ligands
Compound
Rat AhR
Ki (nM)
Human AhR
Ki (nM)
TCDD 0.55 [0.15-2.1] 15.4  [9.1-26]
2,3,7,8-tetrachlorodibenzofuran 0.36 [0.097-1.4] 6.27 [4.4-8.9]
1,2,3,7,8-pentachlorodibenzo-p-dioxin 0.46 [0.3-0.71] 7.62 [4.7-12]
2,3,4,7,8-pentachlorodibenzofuran 1.5 [0.99-1.71] 14.1 [8.1-24]
PCB126 24.7 [15-42] 736 [410-1300]
Competitive binding assays were carried out using rat or human AhR, as 
described in materials and methods. Each experiment was carried out in 
triplicate, and results are the mean, with 95% confidence limits shown in square 
brackets. 21/2/09 PAGE 20
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